Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""immune checkpoint"" wg kryterium: Temat


Tytuł :
Identification of immune checkpoint and cytokine signatures associated with the response to immune checkpoint blockade in gastrointestinal cancers.
Autorzy :
Zhao C; Academy of Military Medical Sciences, Academy of Military Sciences, Beijing, China.; Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, No. 8 East Street, Fengtai District, Beijing, 100071, China.
Wu L; Genecast Biotechnology Co., Ltd, 88 Danshan Road, Xidong Chuangrong Building, Suite C 1310-1318, Xishan District, Wuxi, China.
Liang D; Genecast Biotechnology Co., Ltd, 88 Danshan Road, Xidong Chuangrong Building, Suite C 1310-1318, Xishan District, Wuxi, China.
Chen H; Genecast Biotechnology Co., Ltd, 88 Danshan Road, Xidong Chuangrong Building, Suite C 1310-1318, Xishan District, Wuxi, China.
Ji S; Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, No. 8 East Street, Fengtai District, Beijing, 100071, China.
Zhang G; Genecast Biotechnology Co., Ltd, 88 Danshan Road, Xidong Chuangrong Building, Suite C 1310-1318, Xishan District, Wuxi, China.
Yang K; Genecast Biotechnology Co., Ltd, 88 Danshan Road, Xidong Chuangrong Building, Suite C 1310-1318, Xishan District, Wuxi, China.
Hu Y; Center of Integrative Medicine, Capital Medical University Affiliated Beijing Ditan Hospital, Beijing, China.
Mao B; Genecast Biotechnology Co., Ltd, 88 Danshan Road, Xidong Chuangrong Building, Suite C 1310-1318, Xishan District, Wuxi, China.
Liu T; Department of Medical Oncology, Zhongshan Hospital Fudan University, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China.
Yu Y; Department of Medical Oncology, Zhongshan Hospital Fudan University, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China. .
Zhang H; Institute of Infectious Diseases, Capital Medical University Affiliated Beijing Ditan Hospital, Jingshundongjie 8, Beijing, 100015, China. .
Xu J; Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, No. 8 East Street, Fengtai District, Beijing, 100071, China. .
Pokaż więcej
Źródło :
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2021 Sep; Vol. 70 (9), pp. 2669-2679. Date of Electronic Publication: 2021 Feb 23.
Typ publikacji :
Journal Article
MeSH Terms :
Biomarkers, Tumor*
Cytokines/*metabolism
Gastrointestinal Neoplasms/*etiology
Immune Checkpoint Proteins/*metabolism
Computational Biology ; Cytokines/genetics ; Gastrointestinal Neoplasms/diagnosis ; Gastrointestinal Neoplasms/drug therapy ; Gastrointestinal Neoplasms/metabolism ; Gene Expression Profiling ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Immune Checkpoint Proteins/genetics ; Immunohistochemistry ; Kaplan-Meier Estimate ; Male ; Prognosis ; Reproducibility of Results ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Immune Checkpoint Inhibitors in Human Glioma Microenvironment.
Autorzy :
Ghouzlani A; Cellular and Molecular Pathology Laboratory, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco.
Kandoussi S; Cellular and Molecular Pathology Laboratory, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco.
Tall M; Cellular and Molecular Pathology Laboratory, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco.
Reddy KP; Cellular and Molecular Pathology Laboratory, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco.; Faculty of Medicine, Medical University of Pleven, Pleven, Bulgaria.
Rafii S; Cellular and Molecular Pathology Laboratory, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco.
Badou A; Cellular and Molecular Pathology Laboratory, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 Jul 09; Vol. 12, pp. 679425. Date of Electronic Publication: 2021 Jul 09 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Brain Neoplasms/*drug therapy
Brain Neoplasms/*pathology
Glioma/*drug therapy
Glioma/*pathology
Immune Checkpoint Inhibitors/*therapeutic use
Tumor Microenvironment/*drug effects
Biomarkers, Tumor ; Brain/drug effects ; Brain/immunology ; Brain/metabolism ; Brain/pathology ; Brain Neoplasms/etiology ; Brain Neoplasms/mortality ; Disease Susceptibility ; Glioma/etiology ; Glioma/mortality ; Humans ; Immune Checkpoint Inhibitors/administration & dosage ; Immune Checkpoint Inhibitors/adverse effects ; Immune Checkpoint Proteins/genetics ; Immune Checkpoint Proteins/metabolism ; Molecular Targeted Therapy ; Prognosis ; Treatment Outcome ; Tumor Microenvironment/genetics ; Tumor Microenvironment/immunology
Czasopismo naukowe
Tytuł :
A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.
Autorzy :
Zhou X; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Du J; National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Liu C; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Zeng H; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Chen Y; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Liu L; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Wu D; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 Jul 09; Vol. 12, pp. 688215. Date of Electronic Publication: 2021 Jul 09 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Biomarkers, Tumor/*genetics
Immune Checkpoint Proteins/*genetics
NK Cell Lectin-Like Receptor Subfamily B/*genetics
Neoplasms/*genetics
Biomarkers, Tumor/metabolism ; Chemokines/genetics ; Chemokines/metabolism ; Databases, Genetic ; Disease-Free Survival ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immune Checkpoint Proteins/metabolism ; Immunotherapy ; Lymphocytes, Tumor-Infiltrating/immunology ; Lymphocytes, Tumor-Infiltrating/metabolism ; Molecular Targeted Therapy ; NK Cell Lectin-Like Receptor Subfamily B/metabolism ; Neoplasms/immunology ; Neoplasms/metabolism ; Neoplasms/therapy ; Predictive Value of Tests ; Progression-Free Survival ; RNA-Seq ; Receptors, Chemokine/genetics ; Receptors, Chemokine/metabolism ; Risk Assessment ; Risk Factors ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment.
Autorzy :
Hudson K; Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, United Kingdom.
Cross N; Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, United Kingdom.
Jordan-Mahy N; Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, United Kingdom.
Leyland R; Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, United Kingdom.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2020 Oct 21; Vol. 11, pp. 568931. Date of Electronic Publication: 2020 Oct 21 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Immune Checkpoint Proteins*
B7-H1 Antigen/*metabolism
Programmed Cell Death 1 Receptor/*metabolism
Animals ; Antineoplastic Agents/immunology ; Antineoplastic Agents/therapeutic use ; B7-H1 Antigen/genetics ; Biomarkers, Tumor ; Energy Metabolism ; Epigenesis, Genetic/drug effects ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Immunomodulation/drug effects ; Immunomodulation/genetics ; Molecular Targeted Therapy ; Neoplasm Metastasis ; Neoplasms/drug therapy ; Neoplasms/etiology ; Neoplasms/metabolism ; Neoplasms/pathology ; Programmed Cell Death 1 Receptor/genetics ; Signal Transduction/drug effects
Czasopismo naukowe
Tytuł :
Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management.
Autorzy :
Zhang Q; Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.; Department of Postgraduate Student, West China Hospital, Sichuan University, Chengdu, China.
Tang L; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Zhou Y; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
He W; Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China.
Li W; Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 May 28; Vol. 12, pp. 663986. Date of Electronic Publication: 2021 May 28 (Print Publication: 2021).
Typ publikacji :
Journal Article; Meta-Analysis; Review
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*complications
Immune Checkpoint Inhibitors/*adverse effects
Lung Neoplasms/*complications
Pneumonia/*diagnosis
Pneumonia/*etiology
Pneumonia/*therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/etiology ; Complement System Proteins/immunology ; Complement System Proteins/metabolism ; Disease Management ; Disease Susceptibility ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immune Checkpoint Proteins/genetics ; Immune Checkpoint Proteins/metabolism ; Incidence ; Lung Neoplasms/drug therapy ; Lung Neoplasms/etiology ; Lymphocyte Activation/genetics ; Lymphocyte Activation/immunology ; Prognosis ; Severity of Illness Index ; T-Lymphocytes/drug effects ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism
Czasopismo naukowe
Tytuł :
Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy.
Autorzy :
Zhang QJ; Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Luan JC; Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Song LB; Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Cong R; Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Ji CJ; Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zhou X; Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xia JD; Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Song NH; Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.; Department of Urology, The Affiliated Kezhou People's Hospital of Nanjing Medical University, Xinjiang, China.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 Apr 15; Vol. 12, pp. 657575. Date of Electronic Publication: 2021 Apr 15 (Print Publication: 2021).
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
MeSH Terms :
Biomarkers, Tumor*
Molecular Targeted Therapy*
Immune Checkpoint Inhibitors/*therapeutic use
Neoplasms/*drug therapy
Neoplasms/*etiology
Age Factors ; Disease Susceptibility ; Gene Expression Profiling/methods ; Genomics/methods ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Proteins/genetics ; Immune Checkpoint Proteins/metabolism ; Neoplasms/diagnosis ; Neoplasms/metabolism ; Organ Specificity/genetics ; Organ Specificity/immunology ; Prognosis ; Reproducibility of Results ; Treatment Outcome
Czasopismo naukowe
Tytuł :
The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation.
Autorzy :
Köhler N; Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, Albert Ludwigs University (ALU), Freiburg, Germany.
Ruess DA; Department of General and Visceral Surgery, Center of Surgery, Medical Center - University of Freiburg, Faculty of Medicine, ALU, Freiburg, Germany.
Kesselring R; Department of General and Visceral Surgery, Center of Surgery, Medical Center - University of Freiburg, Faculty of Medicine, ALU, Freiburg, Germany.
Zeiser R; Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, Albert Ludwigs University (ALU), Freiburg, Germany.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 Mar 05; Vol. 12, pp. 634435. Date of Electronic Publication: 2021 Mar 05 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Hematopoietic Stem Cell Transplantation/*adverse effects
Immune Checkpoint Proteins/*metabolism
Leukemia/*surgery
Animals ; Graft vs Host Disease/immunology ; Graft vs Host Disease/metabolism ; Graft vs Leukemia Effect ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Leukemia/genetics ; Leukemia/immunology ; Leukemia/metabolism ; Recurrence ; Transplantation, Homologous/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
Autorzy :
Liu L; Department of Obstetrics and Gynecology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China.
You X; Department of Obstetrics and Gynecology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China.
Han S; Department of Obstetrics and Gynecology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China.
Sun Y; Department of Obstetrics and Gynecology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China.
Zhang J; Department of Obstetrics and Gynecology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China.
Zhang Y; Department of Obstetrics and Gynecology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China.
Pokaż więcej
Źródło :
Oncology reports [Oncol Rep] 2021 Mar; Vol. 45 (3), pp. 835-845. Date of Electronic Publication: 2021 Jan 19.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Immune Checkpoint Proteins/*metabolism
Neoplasms/*immunology
Receptors, Immunologic/*metabolism
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; CD4-Positive T-Lymphocytes/drug effects ; CD4-Positive T-Lymphocytes/immunology ; CD4-Positive T-Lymphocytes/metabolism ; CD8-Positive T-Lymphocytes/drug effects ; CD8-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/metabolism ; Cell Adhesion/drug effects ; Cell Adhesion/immunology ; Disease Progression ; Gene Expression Regulation, Neoplastic/immunology ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Immune Checkpoint Proteins/genetics ; Killer Cells, Natural/immunology ; Killer Cells, Natural/metabolism ; Neoplasms/drug therapy ; Neoplasms/pathology ; Receptors, Immunologic/antagonists & inhibitors ; Receptors, Immunologic/genetics ; Up-Regulation
Czasopismo naukowe
Tytuł :
Genetically Engineered Mouse Models Support a Major Role of Immune Checkpoint-Dependent Immunosurveillance Escape in B-Cell Lymphomas.
Autorzy :
Lemasson Q; UMR CNRS 7276/INSERM U1262 CRIBL, University of Limoges, Limoges, France.; Hematology Laboratory of Dupuytren Hospital University Center (CHU) of Limoges, Limoges, France.
Akil H; UMR CNRS 7276/INSERM U1262 CRIBL, University of Limoges, Limoges, France.; Hematology Laboratory of Dupuytren Hospital University Center (CHU) of Limoges, Limoges, France.
Feuillard J; UMR CNRS 7276/INSERM U1262 CRIBL, University of Limoges, Limoges, France.; Hematology Laboratory of Dupuytren Hospital University Center (CHU) of Limoges, Limoges, France.
Vincent-Fabert C; UMR CNRS 7276/INSERM U1262 CRIBL, University of Limoges, Limoges, France.; Hematology Laboratory of Dupuytren Hospital University Center (CHU) of Limoges, Limoges, France.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 May 25; Vol. 12, pp. 669964. Date of Electronic Publication: 2021 May 25 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Tumor Escape*/drug effects
Tumor Escape*/genetics
Immune Checkpoint Proteins/*immunology
Lymphoma, B-Cell/*immunology
Tumor Microenvironment/*immunology
Animals ; Gene Expression Regulation, Neoplastic ; Immune Checkpoint Inhibitors/therapeutic use ; Immune Checkpoint Proteins/genetics ; Immune Checkpoint Proteins/metabolism ; Immunotherapy ; Lymphoma, B-Cell/drug therapy ; Lymphoma, B-Cell/genetics ; Lymphoma, B-Cell/metabolism ; Mice, Transgenic ; Signal Transduction ; Tumor Microenvironment/genetics
Czasopismo naukowe
Tytuł :
Depleting Tumor Cells Expressing Immune Checkpoint Ligands-A New Approach to Combat Cancer.
Autorzy :
Marcucci F; Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Trentacoste 2, 20134 Milan, Italy.
Rumio C; Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Trentacoste 2, 20134 Milan, Italy.
Pokaż więcej
Źródło :
Cells [Cells] 2021 Apr 12; Vol. 10 (4). Date of Electronic Publication: 2021 Apr 12.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Immune Checkpoint Proteins/*metabolism
Neoplasms/*pathology
Antibodies, Neoplasm/metabolism ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Ligands ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Thinking Small: Small Molecules as Potential Synergistic Adjuncts to Checkpoint Inhibition in Melanoma.
Autorzy :
Chacon AC; Department of Surgery, University of Rochester Medical Center, Rochester, NY 14642, USA.
Melucci AD; Department of Surgery, University of Rochester Medical Center, Rochester, NY 14642, USA.
Qin SS; Department of Microbiology & Immunology, University of Rochester School of Medicine & Dentistry, Rochester, NY 14642, USA.
Prieto PA; Department of Surgery, University of Rochester Medical Center, Rochester, NY 14642, USA.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Mar 22; Vol. 22 (6). Date of Electronic Publication: 2021 Mar 22.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Drug Discovery*/methods
Antineoplastic Agents/*pharmacology
Immune Checkpoint Inhibitors/*pharmacology
Angiogenesis Inhibitors/pharmacology ; Animals ; Antineoplastic Agents/chemistry ; Biomarkers, Tumor ; Cell Line, Tumor ; Drug Synergism ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Immune Checkpoint Proteins/genetics ; Immune Checkpoint Proteins/metabolism ; Immunomodulation/drug effects ; Melanoma/drug therapy ; Melanoma/etiology ; Melanoma/metabolism ; Molecular Targeted Therapy ; Protein Kinase Inhibitors/pharmacology
Czasopismo naukowe
Tytuł :
Phenotypic and Functional Analyses Guiding Combination Immune Checkpoint Immunotherapeutic Strategies in HTLV-1 Infection.
Autorzy :
Clements DM; Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, United States.
Crumley B; Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States.
Chew GM; Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, United States.
Davis E; Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States.
Bruhn R; Department of Medicine and Department of Laboratory Medicine, University of California at San Francisco, San Francisco, CA, United States.; Vitalant Research Institute, San Francisco, CA, United States.
Murphy EL; Department of Medicine and Department of Laboratory Medicine, University of California at San Francisco, San Francisco, CA, United States.; Vitalant Research Institute, San Francisco, CA, United States.
Ndhlovu LC; Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, United States.
Jain P; Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 Mar 09; Vol. 12, pp. 608890. Date of Electronic Publication: 2021 Mar 09 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Anti-Retroviral Agents/*pharmacology
HTLV-I Infections/*genetics
HTLV-I Infections/*immunology
Human T-lymphotropic virus 1/*drug effects
Human T-lymphotropic virus 1/*immunology
Immune Checkpoint Inhibitors/*pharmacology
Adult ; Anti-Retroviral Agents/therapeutic use ; Biomarkers ; Clinical Decision-Making ; Cytokines ; Disease Management ; Drug Therapy, Combination ; Female ; Gene Expression Regulation/drug effects ; HTLV-I Infections/drug therapy ; HTLV-I Infections/virology ; Host-Pathogen Interactions/immunology ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immune Checkpoint Proteins/genetics ; Immune Checkpoint Proteins/metabolism ; Immunologic Memory ; Immunophenotyping ; Leukocytes, Mononuclear/immunology ; Leukocytes, Mononuclear/metabolism ; Lymphocyte Count ; Male ; Middle Aged ; T-Lymphocyte Subsets/drug effects ; T-Lymphocyte Subsets/immunology ; T-Lymphocyte Subsets/metabolism ; Treatment Outcome ; Viral Load
Czasopismo naukowe
Tytuł :
Highly Multiplexed Phenotyping of Immunoregulatory Proteins in the Tumor Microenvironment by CODEX Tissue Imaging.
Autorzy :
Phillips D; Department of Pathology, Stanford University School of Medicine, Stanford, CA, United States.; Department of Dermatology, Stanford University School of Medicine, Stanford, CA, United States.
Schürch CM; Department of Pathology, Stanford University School of Medicine, Stanford, CA, United States.; Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany.
Khodadoust MS; Division of Oncology, Stanford University School of Medicine, Stanford, CA, United States.
Kim YH; Department of Dermatology, Stanford University School of Medicine, Stanford, CA, United States.; Division of Oncology, Stanford University School of Medicine, Stanford, CA, United States.
Nolan GP; Department of Pathology, Stanford University School of Medicine, Stanford, CA, United States.
Jiang S; Department of Pathology, Stanford University School of Medicine, Stanford, CA, United States.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 May 19; Vol. 12, pp. 687673. Date of Electronic Publication: 2021 May 19 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Fluorescent Antibody Technique*
Single-Cell Analysis*
Tissue Array Analysis*
Tumor Microenvironment*
Biomarkers, Tumor/*analysis
Immune Checkpoint Proteins/*analysis
Lymphoma, T-Cell, Cutaneous/*immunology
Skin Neoplasms/*immunology
Clinical Decision-Making ; High-Throughput Screening Assays ; Humans ; Image Processing, Computer-Assisted ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy ; Lymphoma, T-Cell, Cutaneous/drug therapy ; Lymphoma, T-Cell, Cutaneous/pathology ; Microscopy, Fluorescence ; Predictive Value of Tests ; Skin Neoplasms/drug therapy ; Skin Neoplasms/pathology
Czasopismo naukowe
Tytuł :
TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
Autorzy :
Raphael I; Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, United States.
Kumar R; Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, United States.
McCarl LH; Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, United States.
Shoger K; Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, United States.
Wang L; Departments of Neurological Surgery, University of California, San Francisco, CA, United States.
Sandlesh P; Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, United States.
Sneiderman CT; Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, United States.
Allen J; Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, United States.
Zhai S; University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center Biostatistics Facility, University of Pittsburgh, Pittsburgh, PA, United States.
Campagna ML; Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, United States.
Foster A; Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, United States.
Bruno TC; Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA, United States.
Agnihotri S; Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, United States.
Hu B; Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, United States.
Castro BA; Departments of Neurology, University of Chicago, Chicago, IL, United States.
Lieberman FS; Department of Neurology, University of Pittsburgh, Pittsburgh, PA, United States.
Broniscer A; Department of Pediatrics, Division of Health Informatics, Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.
Diaz AA; Departments of Neurological Surgery, University of California, San Francisco, CA, United States.
Amankulor NM; Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, United States.
Rajasundaram D; Department of Pediatrics, Division of Health Informatics, Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.
Pollack IF; Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, United States.
Kohanbash G; Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, United States.; Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA, United States.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 May 07; Vol. 12, pp. 637146. Date of Electronic Publication: 2021 May 07 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Brain Neoplasms/*immunology
Glioblastoma/*immunology
Immune Checkpoint Inhibitors/*pharmacology
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Receptors, Immunologic/*antagonists & inhibitors
Animals ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/metabolism ; CD8-Positive T-Lymphocytes/immunology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Humans ; Immune Checkpoint Proteins/metabolism ; Immunotherapy/methods ; Lymphocytes, Tumor-Infiltrating/metabolism ; Mice ; Mice, Inbred C57BL ; Myeloid-Derived Suppressor Cells/drug effects ; Programmed Cell Death 1 Receptor/metabolism ; Receptors, Immunologic/metabolism ; Tumor Microenvironment/drug effects ; Tumor Microenvironment/immunology
Czasopismo naukowe
Tytuł :
PD-1 Blockade Modulates Functional Activities of Exhausted-Like T Cell in Patients With Cutaneous Leishmaniasis.
Autorzy :
Garcia de Moura R; Núcleo de Doenças Infecciosas, Universidade Federal do Espírito Santo, Vitoria, Brazil.
Covre LP; Núcleo de Doenças Infecciosas, Universidade Federal do Espírito Santo, Vitoria, Brazil.; Division of Medicine, University College London, London, United Kingdom.
Fantecelle CH; Núcleo de Doenças Infecciosas, Universidade Federal do Espírito Santo, Vitoria, Brazil.
Gajardo VAT; Núcleo de Doenças Infecciosas, Universidade Federal do Espírito Santo, Vitoria, Brazil.
Cunha CB; Núcleo de Doenças Infecciosas, Universidade Federal do Espírito Santo, Vitoria, Brazil.
Stringari LL; Núcleo de Doenças Infecciosas, Universidade Federal do Espírito Santo, Vitoria, Brazil.
Belew AT; Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD, United States.; Center for Bioinformatics and Computational Biology, University of Maryland, College Park, MD, United States.
Daniel CB; Núcleo de Biotecnologia, Universidade Federal do Espírito Santo, Vitoria, Brazil.
Zeidler SVV; Núcleo de Biotecnologia, Universidade Federal do Espírito Santo, Vitoria, Brazil.
Tadokoro CE; Universidade Vila Velha, Vila Velha, Brazil.
de Matos Guedes HL; Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.; Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Zanotti RL; Secretaria Estadual de Saúde do Espírito Santo-SESA, Vitoria, Brazil.
Mosser D; Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD, United States.
Falqueto A; Departamento de Medicina Social, Universidade Federal do Espírito Santo, Vitoria, Brazil.
Akbar AN; Division of Medicine, University College London, London, United Kingdom.
Gomes DCO; Núcleo de Doenças Infecciosas, Universidade Federal do Espírito Santo, Vitoria, Brazil.; Núcleo de Biotecnologia, Universidade Federal do Espírito Santo, Vitoria, Brazil.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 Mar 09; Vol. 12, pp. 632667. Date of Electronic Publication: 2021 Mar 09 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Immune Checkpoint Inhibitors/*pharmacology
Leishmaniasis, Cutaneous/*immunology
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
T-Lymphocytes/*drug effects
Adult ; Cell Proliferation/drug effects ; Female ; Humans ; Immune Checkpoint Proteins/metabolism ; Immunosenescence ; Inflammation ; Interferon-gamma/immunology ; Leishmania braziliensis/pathogenicity ; Male ; Middle Aged ; Programmed Cell Death 1 Receptor/metabolism ; Skin/immunology ; T-Lymphocyte Subsets/drug effects ; T-Lymphocyte Subsets/immunology ; T-Lymphocyte Subsets/metabolism ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism
Czasopismo naukowe
Tytuł :
Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors.
Autorzy :
Zhong L; Department of Oncology, The First Affiliated Hospital of Fujian Medical University, No. 20 Chazhong Road, Taijiang District, Fuzhou, 350005, China.; Department of Oncology, The Second Hospital of Longyan, Fujian, 364000, China.
Wu Q; Department of Oncology, The First Affiliated Hospital of Fujian Medical University, No. 20 Chazhong Road, Taijiang District, Fuzhou, 350005, China.
Chen F; Department of Gynecology, The First Hospital of Longyan, Fujian, 364000, China.
Liu J; Department of Oncology, The First Affiliated Hospital of Fujian Medical University, No. 20 Chazhong Road, Taijiang District, Fuzhou, 350005, China.
Xie X; Department of Oncology, The First Affiliated Hospital of Fujian Medical University, No. 20 Chazhong Road, Taijiang District, Fuzhou, 350005, China. .; Molecular Oncology Research Institute, First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, China. .
Pokaż więcej
Źródło :
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2021 Sep; Vol. 70 (9), pp. 2559-2576. Date of Electronic Publication: 2021 Feb 12.
Typ publikacji :
Journal Article; Meta-Analysis; Review
MeSH Terms :
Drug-Related Side Effects and Adverse Reactions/*etiology
Immune Checkpoint Inhibitors/*adverse effects
Molecular Targeted Therapy/*adverse effects
Neoplasms/*complications
Drug-Related Side Effects and Adverse Reactions/diagnosis ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Humans ; Immune Checkpoint Inhibitors/administration & dosage ; Immune Checkpoint Inhibitors/therapeutic use ; Incidence ; Molecular Targeted Therapy/methods ; Neoplasms/diagnosis ; Neoplasms/drug therapy ; Neoplasms/mortality ; Odds Ratio ; Prognosis ; Severity of Illness Index
Czasopismo naukowe
Tytuł :
LAG3's Enigmatic Mechanism of Action.
Autorzy :
Graydon CG; Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada.
Mohideen S; Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada.
Fowke KR; Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada.; Department of Medical Micobiology, University of Nairobi, Nairobi, Kenya.; Department of Community Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada.; Partners for Health and Development in Africa, Nairobi, Kenya.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 Jan 08; Vol. 11, pp. 615317. Date of Electronic Publication: 2021 Jan 08 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Antigens, CD/*physiology
Immune Checkpoint Proteins/*physiology
ADAM10 Protein/metabolism ; ADAM17 Protein/metabolism ; Amino Acid Motifs ; Antigens, CD/chemistry ; Clinical Trials as Topic ; Dendritic Cells/metabolism ; Endocytosis ; Gene Expression Regulation ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immune Checkpoint Proteins/chemistry ; Ligands ; Lymphocyte Subsets/metabolism ; Molecular Targeted Therapy ; Neoplasms/drug therapy ; Neoplasms/immunology ; Neurons/metabolism ; Protein Biosynthesis ; Protein Processing, Post-Translational ; Receptors, Antigen, T-Cell/physiology ; Transcription, Genetic
Czasopismo naukowe
Tytuł :
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
Autorzy :
Querfeld C; Division of Dermatology, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA. Electronic address: .
Thompson JA; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Taylor MH; Earle A Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.
DeSimone JA; Melanoma and Skin Oncology Center, Inova Health System, Fairfax, VA, USA.
Zain JM; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.
Shustov AR; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Johns C; School of Medicine, Oregon Health and Science University, Portland, OR, USA.
McCann S; Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Lin GHY; Trillium Therapeutics, Mississauga, ON, Canada.
Petrova PS; Trillium Therapeutics, Mississauga, ON, Canada.
Uger RA; Trillium Therapeutics, Mississauga, ON, Canada.
Molloy N; Trillium Therapeutics, Mississauga, ON, Canada.
Shou Y; Trillium Therapeutics, Mississauga, ON, Canada.
Akilov OE; Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2021 Nov; Vol. 8 (11), pp. e808-e817. Date of Electronic Publication: 2021 Oct 07.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Multicenter Study
MeSH Terms :
CD47 Antigen/*antagonists & inhibitors
Immune Checkpoint Inhibitors/*therapeutic use
Immunoglobulin G/*therapeutic use
Mycosis Fungoides/*drug therapy
Sezary Syndrome/*drug therapy
Skin Neoplasms/*drug therapy
Aged ; CD47 Antigen/immunology ; Female ; Humans ; Immune Checkpoint Inhibitors/administration & dosage ; Immune Checkpoint Inhibitors/adverse effects ; Immunoglobulin G/administration & dosage ; Immunoglobulin G/adverse effects ; Male ; Maximum Tolerated Dose ; Middle Aged ; Mycosis Fungoides/immunology ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/immunology ; Sezary Syndrome/immunology ; Skin Neoplasms/immunology
Czasopismo naukowe
Tytuł :
Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors.
Autorzy :
Arangalage D; Department of Cardiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland.
Degrauwe N; Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
Michielin O; Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
Monney P; Department of Cardiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland. Electronic address: .
Özdemir BC; Department of Oncology, Bern University Hospital (Inselspital), University of Bern, Switzerland; International Cancer Prevention Institute, Epalinges, Switzerland. Electronic address: .
Pokaż więcej
Źródło :
Cancer treatment reviews [Cancer Treat Rev] 2021 Nov; Vol. 100, pp. 102282. Date of Electronic Publication: 2021 Aug 18.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Cardiotoxicity/*diagnosis
Cardiotoxicity/*drug therapy
Immune Checkpoint Inhibitors/*adverse effects
Mitogen-Activated Protein Kinase Kinases/*antagonists & inhibitors
Protein Kinase Inhibitors/*adverse effects
Proto-Oncogene Proteins B-raf/*antagonists & inhibitors
Adrenal Cortex Hormones/therapeutic use ; Cardiotoxicity/etiology ; Humans ; Immune Checkpoint Inhibitors/administration & dosage ; Myocarditis/chemically induced ; Myocarditis/diagnosis ; Myocarditis/drug therapy ; Protein Kinase Inhibitors/administration & dosage ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł :
The Role of Immune Checkpoint Inhibitors in Leptomeningeal Disease: A Systematic Review.
Autorzy :
Palmisciano P; Department of Neurosurgery, Trauma Center, Gamma Knife Center, Cannizzaro Hospital, Catania, Italy.
Haider AS; Texas A&M University College of Medicine, Houston, TX, U.S.A.
Nwagwu CD; Emory University School of Medicine, Atlanta, GA, U.S.A.
Wahood W; Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Davie, FL, U.S.A.
Yu K; Department of Neurosurgical Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, U.S.A.
Ene CI; Department of Neurosurgery, MD Anderson Cancer Center, Houston, TX, U.S.A.
O'Brien BJ; Department of Neuro-Oncology, MD Anderson Cancer Center, Houston, TX, U.S.A.
Aoun SG; Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, TX, U.S.A.
Cohen-Gadol AA; Department of Neurological Surgery, Indiana University School of Medicine, Indianapolis, IN, U.S.A.
El Ahmadieh TY; Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, TX, U.S.A.; .
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2021 Nov; Vol. 41 (11), pp. 5333-5342.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Immune Checkpoint Inhibitors/*therapeutic use
Meningeal Neoplasms/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Disease Progression ; Female ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Male ; Meningeal Neoplasms/immunology ; Meningeal Neoplasms/mortality ; Meningeal Neoplasms/secondary ; Middle Aged ; Progression-Free Survival ; Risk Assessment ; Risk Factors ; Steroids/adverse effects ; Time Factors ; Tumor Microenvironment
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies